FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509166377> ?p ?o ?g. }

• W2509166377 abstract "This PhD work consists of an in vitro and in vivo part. In the in vivo part, we investigated the role of dopamine in the acute clinical effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects. The role of dopamine in the addictive effects of drug of abuse is well established, but whether it contributes to the acute psychotropic effects of MDMA is unclear. In this pharmacological interaction study, we used the dopamine and weak norepinephrine transporter inhibitor bupropion (Stahl et al. 2004) as a pharmacological tool to block the MDMA-induced dopamine release and to study the role of dopamine in the effects of MDMA. We hypothesized that bupropion would decrease the subjective effects of MDMA to the extent that they depend on MDMA-induced release of dopamine. We included 16 healthy human subjects in this double-blind, placebo-controlled, crossover study. Bupropion pretreatment slightly increased MDMA plasma concentration and prolonged but not reduced the subjective effects contrary to our hypothesis. Additionally, bupropion reduced the MDMA-induced elevations in plasma norepinephrine concentrations and the heart rate response to MDMA. These findings support a role for norepinephrine in the MDMA-induced cardiostimulant effects but no role for MDMA-induced transporter-mediated dopamine release in the elevated mood effects after MDMA administration. Possibly, most of the acute psychotropic effects of MDMA are mediated via transporter-mediated release of serotonin and norepinephrine as previously shown (Hysek et al. 2011, Hysek et al. 2012).In the second and main part of this work we characterized the pharmacological profiles of novel psychoactive substances (NPS). Specifically, we studied whether and how potently NPS interacted with the human transporters for norepinephrine, dopamine, and serotonin, stably expressed in human embryonic kidney (HEK293) cells. Additionally, we assessed binding affinity to the serotonin 5-HT1A, 5-HT2A, 5-HT2C-receptors and the activation potency and activation efficacy at 5-HT2A and 5-HT2B receptors. Furthermore, binding to alpha1A/2A-adrenergic, dopamine D1-3, histamine H1 receptors, as well as trace amine-associated receptor 1 (TAAR1) was also assessed.The NPS studied in this project included para-4-halogenated amphetamine derivatives, which were shown to be relatively more serotonergic than their non-4-halogenated counterparts and pyrovaleronering-substituted cathinones, which were highly potent dopamine transporter inhibitors with a high risk for abuse. Para-halogenated drugs (4-fluoroephedrine, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcathinone, and 4-bromomethcathinone) also released monoamines, similar to MDMA, whereas pyrovalerones were found to be pure uptake inhibitors. Most benzofurans were similar to MDMA but slightly more serotoninergic than MDMA and additionally activated the serotonin 5-HT2B receptor. The last big group of NPS studied in this project, were novel hallucinogens, which predominantly interacted with the 5-HT2A receptor. This serotonin receptor subtype mediates the hallucinogenic and hallucinogenic-like visual effects of classic serotonergic hallucinogens (Vollenweider et al. 1998, Nichols 2004, Halberstadt et al. 2013, Halberstadt et al. 2014, Halberstadt 2015). Compounds tested in this project included the benzodifuran 8-Bromo-2,3,6,7-benzo-dihydro-difuran-ethylamine (2C-B-FLY), 2C-drugs with their highly potent N-(2-methoxy)benzyl (NBOMe)-derivatives, and lysergic acid diethylamide (LSD). Interestingly, NBOMe derivatives displayed higher affinities at the 5-HT2A receptor than LSD, together with a high selectivity for 5-HT2A over the 5-HT1A receptor, contrary to LSD. NBOMes were partial 5-HT2A receptor agonists, similar to LSD. These novel drugs likely carry a high hallucinogenic potential when used recreationally by humans and the high binding to α1A-receptor (Ki < 1µM) may result in additional vasocontrictive and cardiovascular stimulant effects. Taken together, this PhD contributed to the understanding of the role of dopamine in the effects of MDMA, an important recreational substances. Additionally, we characterized the in vitro pharmacology of many novel designer drugs, which will be helpful in the prediction of the clinical toxicological effects of these newly used recreational drugs." @default.
• W2509166377 created "2016-09-16" @default.
• W2509166377 creator A5065551357 @default.
• W2509166377 date "2016-01-01" @default.
• W2509166377 modified "2023-09-23" @default.
• W2509166377 title "Pharmacology of novel psychoactive substances" @default.
• W2509166377 doi "https://doi.org/10.5451/unibas-006616893" @default.
• W2509166377 hasPublicationYear "2016" @default.
• W2509166377 type Work @default.
• W2509166377 sameAs 2509166377 @default.
• W2509166377 citedByCount "0" @default.
• W2509166377 crossrefType "dissertation" @default.
• W2509166377 hasAuthorship W2509166377A5065551357 @default.
• W2509166377 hasConcept C118552586 @default.
• W2509166377 hasConcept C126322002 @default.
• W2509166377 hasConcept C137183658 @default.
• W2509166377 hasConcept C142724271 @default.
• W2509166377 hasConcept C15744967 @default.
• W2509166377 hasConcept C176233148 @default.
• W2509166377 hasConcept C2776755682 @default.
• W2509166377 hasConcept C2777843972 @default.
• W2509166377 hasConcept C2778514916 @default.
• W2509166377 hasConcept C2779488553 @default.
• W2509166377 hasConcept C2779908668 @default.
• W2509166377 hasConcept C2780876324 @default.
• W2509166377 hasConcept C513476851 @default.
• W2509166377 hasConcept C71924100 @default.
• W2509166377 hasConcept C98274493 @default.
• W2509166377 hasConceptScore W2509166377C118552586 @default.
• W2509166377 hasConceptScore W2509166377C126322002 @default.
• W2509166377 hasConceptScore W2509166377C137183658 @default.
• W2509166377 hasConceptScore W2509166377C142724271 @default.
• W2509166377 hasConceptScore W2509166377C15744967 @default.
• W2509166377 hasConceptScore W2509166377C176233148 @default.
• W2509166377 hasConceptScore W2509166377C2776755682 @default.
• W2509166377 hasConceptScore W2509166377C2777843972 @default.
• W2509166377 hasConceptScore W2509166377C2778514916 @default.
• W2509166377 hasConceptScore W2509166377C2779488553 @default.
• W2509166377 hasConceptScore W2509166377C2779908668 @default.
• W2509166377 hasConceptScore W2509166377C2780876324 @default.
• W2509166377 hasConceptScore W2509166377C513476851 @default.
• W2509166377 hasConceptScore W2509166377C71924100 @default.
• W2509166377 hasConceptScore W2509166377C98274493 @default.
• W2509166377 hasLocation W25091663771 @default.
• W2509166377 hasOpenAccess W2509166377 @default.
• W2509166377 hasPrimaryLocation W25091663771 @default.
• W2509166377 hasRelatedWork W134658541 @default.
• W2509166377 hasRelatedWork W1522866645 @default.
• W2509166377 hasRelatedWork W1533710606 @default.
• W2509166377 hasRelatedWork W1536694270 @default.
• W2509166377 hasRelatedWork W1660415633 @default.
• W2509166377 hasRelatedWork W1985253324 @default.
• W2509166377 hasRelatedWork W1993521516 @default.
• W2509166377 hasRelatedWork W2007549333 @default.
• W2509166377 hasRelatedWork W2019474799 @default.
• W2509166377 hasRelatedWork W2021705695 @default.
• W2509166377 hasRelatedWork W2060895955 @default.
• W2509166377 hasRelatedWork W2082609266 @default.
• W2509166377 hasRelatedWork W2089188189 @default.
• W2509166377 hasRelatedWork W2115613596 @default.
• W2509166377 hasRelatedWork W2118100568 @default.
• W2509166377 hasRelatedWork W2319247797 @default.
• W2509166377 hasRelatedWork W2398898762 @default.
• W2509166377 hasRelatedWork W2798025613 @default.
• W2509166377 hasRelatedWork W3081575870 @default.
• W2509166377 hasRelatedWork W2146547795 @default.
• W2509166377 isParatext "false" @default.
• W2509166377 isRetracted "false" @default.
• W2509166377 magId "2509166377" @default.
• W2509166377 workType "dissertation" @default.